OBJECTIVES: The present study investigated whether systemic, low-grade inflammation of metabolic risk contributed to diastolic left ventricular (LV) dysfunction and heart failure with preseved ejection fraction (HFpEF) through coronary microvascular endothelial activation, which alters paracrine signalling to cardiomyocytes and predisposes them to hypertrophy and high diastolic stiffness. BACKGROUND: Metabolic risk is associated with diastolic LV dysfunction and HFpEF. METHODS: We explored inflammatory endothelial activation and its effects on oxidative stress, nitric oxide (NO) bioavailability, and cyclic guanosine monophosphate (cGMP)-protein kinase G (PKG) signalling in myocardial biopsies of HFpEF patients and validated our findings by ...
Overlapping pandemics of lifestyle-related diseases pose a substantial threat to cardiovascular heal...
Background/Objectives: In heart failure pro-inflammatory cytokines contribute to cardiomyocytes loss...
The positive findings of the EMPA-REG OUTCOME trial (Randomized, Placebo-Controlled Cardiovascular O...
OBJECTIVES: The present study investigated whether systemic, low-grade inflammation of metabolic ris...
Over the past decade, myocardial structure, cardiomyocyte function, and intramyocardial signaling we...
BJECTIVE:To investigate the role of oxidative stress, inflammation, hypercoagulability and neuroendo...
Heart failure with preserved ejection fraction (HFpEF) has been recognized as the greatest single un...
Heart failure with preserved ejection fraction (HFpEF) is one of the greatest unmet needs in modern ...
In accordance with the comorbidity-inflammation paradigm, comorbidities and especially metabolic com...
Coronary microvessel endothelial dysfunction and nitric oxide (NO) depletion contribute to elevated ...
While endothelial dysfunction is suggested to contribute to heart failure with preserved ejection fr...
PurposeSystemic inflammation and coronary microvascular dysfunction (CMD) may be causal drivers of h...
Noncardiac comorbidities such as diabetes mellitus (DM) have different outcomes in heart failure wit...
Heart failure with preserved ejection fraction (HFpEF) is an increasingly studied entity accounting ...
Heart failure with preserved ejection fraction (HFpEF) is a complex heterogeneous disease for which ...
Overlapping pandemics of lifestyle-related diseases pose a substantial threat to cardiovascular heal...
Background/Objectives: In heart failure pro-inflammatory cytokines contribute to cardiomyocytes loss...
The positive findings of the EMPA-REG OUTCOME trial (Randomized, Placebo-Controlled Cardiovascular O...
OBJECTIVES: The present study investigated whether systemic, low-grade inflammation of metabolic ris...
Over the past decade, myocardial structure, cardiomyocyte function, and intramyocardial signaling we...
BJECTIVE:To investigate the role of oxidative stress, inflammation, hypercoagulability and neuroendo...
Heart failure with preserved ejection fraction (HFpEF) has been recognized as the greatest single un...
Heart failure with preserved ejection fraction (HFpEF) is one of the greatest unmet needs in modern ...
In accordance with the comorbidity-inflammation paradigm, comorbidities and especially metabolic com...
Coronary microvessel endothelial dysfunction and nitric oxide (NO) depletion contribute to elevated ...
While endothelial dysfunction is suggested to contribute to heart failure with preserved ejection fr...
PurposeSystemic inflammation and coronary microvascular dysfunction (CMD) may be causal drivers of h...
Noncardiac comorbidities such as diabetes mellitus (DM) have different outcomes in heart failure wit...
Heart failure with preserved ejection fraction (HFpEF) is an increasingly studied entity accounting ...
Heart failure with preserved ejection fraction (HFpEF) is a complex heterogeneous disease for which ...
Overlapping pandemics of lifestyle-related diseases pose a substantial threat to cardiovascular heal...
Background/Objectives: In heart failure pro-inflammatory cytokines contribute to cardiomyocytes loss...
The positive findings of the EMPA-REG OUTCOME trial (Randomized, Placebo-Controlled Cardiovascular O...